肝細胞癌的免疫療法

10.6666/ClinMed.202003_85(3).0030

齊振達；黃怡翔

肝細胞癌（hepatocellular carcinoma） ； 免疫檢查點阻斷劑治療法（immune checkpoint blockade therapy） ； 二線治療（second-line treatment） ； 合併治療（combination therapy）

臨床醫學月刊

85卷3期（2020 / 03 / 27）

160 - 165

繁體中文

肝細胞癌（hepatocellular carcinoma）起因於慢性肝臟疾病。儘管許多有效的防止策略，如抗肝炎病毒治療的發展，但由於非酒精性脂肪肝疾病的盛行，肝細胞癌的發生率仍持續上升。許多晚期肝癌病患超出移植、手術切除、甚至局部治療的標準，而現有的治療選擇也只有效於小部分的病患。然而，癌症免疫治療的興起，帶給這類病人新的治療選擇與機會。免疫檢查點阻斷劑治療法（immune checkpoint blockade therapy）是這類免疫治療中最先蓬勃發展的一類，藉由提升自身免疫反應，來對抗腫瘤細胞。免疫檢查點阻斷劑治療法已經在晚期肝癌病人取得令人驚豔的療效。此類藥物已證實在早期臨床試驗上單獨使用有療效外，後續的合併治療效果也是值得令人期待。

1. Abou-Alfa, GK,Meyer, T,Cheng, A-L(2018).Cabozantinib (C) versus placebo(P) in patients(pts) with advanced hepatocellular carcinoma(HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.J Clin Oncol,36
2. Ally, A,Balasundaram, M,Carlsen, R(2017).Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.Cell,169,1327-1341.e23.
3. Asghar, U,Meyer, T(2012).Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?.J Hepatol,56,686-695.
4. Bruix, J,Qin, S,Merle, P(2017).Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet,389,56-66.
5. Cheng, AL,Kang, YK,Chen, Z(2009).Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial.Lancet Oncol,10,25-34.
6. Chuang, W-L,Liu, H-W,Chang, W-Y(1990).Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion.Cancer,65,926-930.
7. Duffy, AG,Ulahannan, SV,Makorova-Rusher, O(2017).Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol,66,545-551.
8. El-Khoueiry, AB,Sangro, B,Yau, T(2017).Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet,389,2492-2502.
9. Eroglu, Z,Zaretsky, JM,Hu-Lieskovan, S(2018).High response rate to PD-1 blockade in desmoplastic melanomas.Nature,553,347.
10. Francisco, LM,Salinas, VH,Brown, KE(2009).PDL1 regulates the development, maintenance, and function of induced regulatory T cells.J Exp Med,206,3015-3029.
11. Fu, J,Xu, D,Liu, Z(2007).Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients.Gastroenterology,132,2328-2339.
12. Gao, Q,Wang, X-Y,Qiu, S-J(2009).Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.Clin Cancer Res,15,971-979.
13. Han, Y,Chen, Z,Yang, Y(2014).Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.Hepatology,59,567-579.
14. Hato, T,Goyal, L,Greten, TF(2014).Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions.Hepatology,60,1776-1782.
15. Hoshida, Y,Villanueva, A,Kobayashi, M(2008).Gene expression in fixed tissues and outcome in hepatocellular carcinoma.N Engl J Med,359,1995-2004.
16. Kelley, RK,Abou-Alfa, GK,Bendell, JC(2017).Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma(HCC): Phase I safety and efficacy analyses.J Clin Oncol,35,4073.
17. Kudo, M,Finn, RS,Qin, S(2018).Lenvatinib versus sorafenib in first-linetreatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet,391,1163-1173.
18. Lilly E. Lilly announces CYRAMZA (ramucirumab) phase 3 REACH-2 study in second-line hepatocellular carcinoma patients met overall survival endpoint. Cision 2018.
19. Llovet, JM,Ricci, S,Mazzaferro, V(2008).Sorafenib in advanced hepatocellular carcinoma.N Engl J Med,359,378-390.
20. Llovet, JM,Villanueva, A,Lachenmayer, A(2015).Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Nat Rev Clin Oncol,12,408-424.
21. Marrero, JA,Kulik, LM,Sirlin, CB(2018).Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology,68,723-750.
22. Nguyen, LT,Ohashi, PS(2015).Clinical blockade of PD1 and LAG3 — potential mechanisms of action.Nat Rev Immunol,15,45-46.
23. Prieto, J,Melero, I,Sangro, B(2015).Immunological landscape and immunotherapy of hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol,12,681-700.
24. Qin, L-X(2012).Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma.Cancer Microenviron,5,203-209.
25. Ringelhan, M,Pfister, D,O'Connor, T(2018).The immunology of hepatocellular carcinoma.Nat Immunol,19,222-232.
26. Sangro, B,Gomez-Martin, C,de la Mata, M(2013).A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.J Hepatol,59,81-88.
27. Shi, F,Shi, M,Zeng, Z(2011).PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.Int J Cancer,128,887-896.
28. Sia, D,Jiao, Y,Martinez-Quetglas, I(2017).Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.Gastroenterology,153,812-826.
29. Sznol, M,Ferrucci, PF,Hogg, D(2017).Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.J Clin Oncol,35,3815-3822.
30. Wing, K,Onishi, Y,Prieto-Martin, P(2008).CTLA-4 Control over Foxp3⁺ Regulatory T Cell Function.Science,322,271-275.
31. Wu, Y,Kuang, D-M,Pan, W-D(2013).Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions.Hepatology,57,1107-1116.
32. Zheng, C,Zheng, L,Yoo, J-K(2017).Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing.Cell,169,1342-1356.
33. Zhu, AX,Finn, RS,Edeline, J(2018).Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol,19,940-952.